Pfizer emerges as preferred 2026 investment over speculative Lexicon in new analysis

An investment analysis published by The Motley Fool compares Lexicon Pharmaceuticals and Pfizer as stock options for 2026, concluding that Pfizer is the preferable investment due to its profitability, cash flow, and valuation, while characterising Lexicon as speculative with significant regulatory risks. The report highlights Pfizer’s strong financial position, citing FY2025 revenue of approximately $62.6 billion and net income of roughly $7.8 billion. In contrast, Lexicon Pharmaceuticals is characterised as speculative, having reported FY2025 revenue of nearly $49.8 million but a net loss of $50.3 million.

Lexicon Pharmaceuticals operates as a smaller biotech player focusing on gene science and chronic conditions, primarily relying on its commercial product INPEFA. In FY2025, the company achieved revenue of nearly $49.8 million, representing a 60% increase from the previous year. Despite this growth, Lexicon reported a net loss of $50.3 million. As of its December 2025 balance sheet, the company held a debt-to-equity ratio of roughly 0.6x and carried an accumulated deficit of nearly $2.0 billion.

Pfizer, a global biopharmaceutical leader with a workforce of nearly 75,000 employees, reported FY2025 revenue of approximately $62.6 billion, a slight decrease of 1.6% from the prior year. The company posted net income of roughly $7.8 billion, resulting in a net margin of close to 12.4%. Its balance sheet showed a debt-to-equity ratio of approximately 0.8x and generated free cash flow of approximately $9.1 billion for the fiscal year.

The analysis notes that Lexicon faces significant regulatory hurdles, particularly regarding the approval process for candidates such as ZYNQUISTA for type 1 diabetes. Furthermore, a single entity, Artal Group, holds roughly 35% of Lexicon’s shares, limiting the influence of smaller retail shareholders. Lexicon’s stock has traded between $1 and $2.50 since July 2025, reflecting the speculative nature of the business. In Q1 2026, Lexicon’s commercial product INPEFA generated just $1.1 million in sales.

Pfizer faces revenue concentration risks, with 12 products accounting for roughly 65% of its 2025 revenue, and patent expirations between 2026 and 2030. However, the company beat Wall Street expectations in Q1 2026 on sales and net income. Pfizer maintains a forward P/E ratio of 8.7 and a dividend yield of approximately 7%. The company is also developing an injectable GLP-1 drug with positive Phase II trial results and has more than $6 billion in cash, positioning it as a more affordable and stable choice compared to Lexicon, which lacks a forward P/E due to its net losses.